Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive surgical therapy with hepatic resection or liver tra...

Full description

Bibliographic Details
Main Authors: Nitin N. Katariya, Blanca C. Lizaola-Mayo, David M. Chascsa, Emmanouil Giorgakis, Bashar A. Aqel, Adyr A. Moss, Pedro Luiz Serrano Uson Junior, Mitesh J. Borad, Amit K. Mathur
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
Hepatocellular Carcinoma (HCC)
immune checkpoint inhibitors
nivolumab
neoadjuvant therapy
Barcelona Clinic Liver Classification (BCLC)
liver transplant
Online Access:https://www.mdpi.com/2072-6694/14/9/2056

Internet

https://www.mdpi.com/2072-6694/14/9/2056

Similar Items